A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin (PRaCTISe-HR)

November 16, 2026 updated by: Tuberculosis Research Centre, India

A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin

This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Trail participants will be monitored for Adverse Drug reactions and clinical and radiological progress weekly during intensive phase and monthly during 1st year follow up and once in 3 months till end of follow up(30th month)

Study Type

Interventional

Enrollment (Estimated)

2500

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Andhra Pradesh
      • Guntur, Andhra Pradesh, India, 522503
        • Recruiting
        • All India Institute of Medical Sciences(AIIMS), Mangalagiri
        • Contact:
    • Assam
      • Guwahati, Assam, India, 781101
        • Active, not recruiting
        • All India Institute of Medical Sciences, Guwahati
    • Gujarat
      • Rajkot, Gujarat, India, 360001
        • Not yet recruiting
        • Govt. PDU Medical College
        • Contact:
      • Surat, Gujarat, India, 395001
        • Active, not recruiting
        • Govt. Medical College and NCH
    • Maharashtra
      • Mumbai, Maharashtra, India, 400008
        • Recruiting
        • Grant Govt. Medical College & Sir JJ Group of Hospitals
        • Contact:
      • Nagpur, Maharashtra, India
        • Not yet recruiting
        • All India Institute Of Medical Sciences, Nagpur
        • Contact:
    • Meghālaya
      • Shillong, Meghālaya, India, 793018
        • Recruiting
        • North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences (NEIGRIHMS)
        • Contact:
    • National Capital Territory of Delhi
      • New Delhi, National Capital Territory of Delhi, India, 110030
        • Not yet recruiting
        • National Institute of TB and Respiratory Diseases
        • Contact:
    • Odisha
      • Bhubaneswar, Odisha, India, 751019
        • Active, not recruiting
        • All India Institute of Medical Sciences (AIIMS), Bhubaneswar
      • Bhubaneswar, Odisha, India, 751001
        • Active, not recruiting
        • Post Graduate Institute of Medical Education & Research, Capital Hospital
    • Tamil Nadu
      • Chennai, Tamil Nadu, India, 600031
        • Recruiting
        • ICMR - National Institute for Research in Tuberculosis
        • Contact:
        • Contact:
        • Principal Investigator:
          • Dr PK Bhavani, MBBS., MPH., PGDBEME
        • Principal Investigator:
          • Dr G Narendran, MBBS., DNB., DTRD., FRCP.,
        • Sub-Investigator:
          • Dr R Balaji, MBBS., MD.,
    • Telangana
      • Hyderabad, Telangana, India, 500038
        • Recruiting
        • Govt. General and Chest Hospital, Osmania Medical College
        • Contact:
    • Uttar Pradesh
      • Agra, Uttar Pradesh, India, 282002
        • Recruiting
        • Sarojini Naidu Medical College
        • Contact:
      • Allahābād, Uttar Pradesh, India, 211002
        • Recruiting
        • Moti Lal Nehru Medical College
        • Contact:
      • Lucknow, Uttar Pradesh, India, 226003
        • Recruiting
        • King George Medical University
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 70 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Individuals aged equal or above 14 years.
  2. Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
  3. Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
  4. If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
  5. Willing to follow the trial procedures

Exclusion Criteria:

  1. Body weight less than 30 kg in adults

  2. Anti-TB treatment, >14 days for the current illness

  3. Known Resistance to rifampicin & Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA

  4. Patients with serious forms of Extra-pulmonary TB

  5. HIV Patients on second line ART regimens.

  6. Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities

    • ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria)
    • Serum Creatinine >1.2 mg/dl.
  7. Pregnant or lactating mothers

  8. Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability

  9. Patients with h/o of concomitant medications which may interfere with study drugs

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: 2H R25 ZE /4 H R10 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Experimental: 2 H R25 ZE/ 4 H R25 E

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol

Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol

Usage of High dose Rifampicin given for 2 months (only during Intensive Phase) along with other first line anti-TB drugs.

Usage of High dose Rifampicin given for 6 months (Both Intensive and Continuation Phase) along with other first line anti-TB drugs.

Experimental: 2 H R25 ZE L/2 H R25 E L

Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg)

Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.

Usage of High dose Rifampicin and Levofloxacin for 4 months along with other first line anti-TB drugs.

Active Comparator: 2 H R10 ZE /4H R10 E

Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol

Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol

Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol and Four months of Rifampicin, Isoniazid, and Ethambutol

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Proportion of patients cured and disease (recurrence) free and alive at 18 months post randomization
Time Frame: Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization
Cure - At End of Treatment (4 or 6 months) & Recurrence - At 18 months post randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of patients with grade 3 or 4 adverse drug reactions.
Time Frame: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients who require permanent change of high dose regimen to standard regimen due to adverse events
Time Frame: Through treatment completion, an average of 24 weeks
Through treatment completion, an average of 24 weeks
The proportion of PTB patients -with smear & culture conversion at end of 2 months & at end of treatment -with radiological clearance at 2 months & at end of treatment
Time Frame: At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
At 18 months (Post randomisation) At 2 Years (Post treatment) Both time points are for relapse.
The proportion of patients with drug interactions between the high dose Rifampicin & other first line anti-TB drugs & concomitant medications
Time Frame: At 1st Month
At 1st Month
The cost effectiveness of different treatment regimens
Time Frame: Through treatment completion, an average of 24 weeks

Direct and indirect costs incurred by patient, health system and to identify the factors contributing to the cost in the management of TB.

Through treatment completion, an average of 24 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Dr PK Bhavani, MBBS., MPH., PGDBEME, ICMR - National Institute for Research in Tuberculosis
  • Principal Investigator: Dr G Narendran, MBBS., DNB., DTRD., FRCP.,, ICMR - National Institute for Research in Tuberculosis

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 6, 2026

Primary Completion (Estimated)

December 1, 2028

Study Completion (Estimated)

December 1, 2029

Study Registration Dates

First Submitted

November 9, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.